Shelter Ins Retirement Plan bought a new position in Cigna Corp (NYSE:CI) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,446 shares of the health services provider’s stock, valued at approximately $1,224,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CI. 1 North Wealth Services LLC bought a new position in shares of Cigna in the fourth quarter valued at approximately $25,000. Private Ocean LLC bought a new position in shares of Cigna in the fourth quarter valued at approximately $26,000. Delta Asset Management LLC TN bought a new position in shares of Cigna in the fourth quarter valued at approximately $28,000. Litman Gregory Asset Management LLC bought a new position in shares of Cigna in the fourth quarter valued at approximately $30,000. Finally, Parisi Gray Wealth Management bought a new position in shares of Cigna in the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 93.44% of the company’s stock.
CI stock opened at $169.56 on Friday. Cigna Corp has a 12 month low of $162.42 and a 12 month high of $226.60. The company has a market cap of $64.80 billion, a P/E ratio of 11.92, a price-to-earnings-growth ratio of 0.81 and a beta of 0.73. The company has a quick ratio of 0.42, a current ratio of 0.42 and a debt-to-equity ratio of 0.96.
The firm also recently announced a special dividend, which will be paid on Wednesday, April 10th. Investors of record on Monday, March 11th will be paid a dividend of $0.04 per share. The ex-dividend date of this dividend is Friday, March 8th. Cigna’s dividend payout ratio is presently 0.28%.
Several research analysts have recently issued reports on CI shares. Credit Suisse Group reiterated a “buy” rating and issued a $250.00 price objective on shares of Cigna in a report on Monday, January 7th. Barclays reiterated a “buy” rating and issued a $220.00 price objective on shares of Cigna in a report on Sunday, January 6th. Zacks Investment Research upgraded shares of Cigna from a “hold” rating to a “buy” rating and set a $208.00 price objective for the company in a report on Friday, January 4th. Edward Jones started coverage on shares of Cigna in a report on Wednesday, January 2nd. They issued a “buy” rating for the company. Finally, Goldman Sachs Group reiterated a “buy” rating on shares of Cigna in a report on Saturday, February 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $231.28.
In related news, insider Michael W. Triplett sold 9,148 shares of the company’s stock in a transaction that occurred on Monday, February 11th. The shares were sold at an average price of $181.01, for a total value of $1,655,879.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian C. Evanko purchased 2,000 shares of Cigna stock in a transaction that occurred on Monday, March 11th. The stock was purchased at an average price of $163.40 per share, with a total value of $326,800.00. The disclosure for this purchase can be found here. 1.10% of the stock is owned by corporate insiders.
Cigna Company Profile
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.
Featured Article: Why is the ex-dividend date different from the record date?
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.